Q32 Bio
21 articles with Q32 Bio
-
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
10/27/2022
Q32 Bio and Horizon Therapeutics plc, announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multi-center proof-of-concept study in adult subjects to evaluate the safety and efficacy of ADX-914 in persistent, moderate-to-severe atopic dermatitis.
-
Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition
9/20/2022
Q32 Bio announced the appointment of Jodie Morrison as Board Member and Acting Chief Executive Officer, succeeding Michael Broxson.
-
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
8/15/2022
Q32 Bio and Horizon Therapeutics plc, announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.
-
Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097
6/23/2022
Data show that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition.
-
Shelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia "Resolution of Inflammation" Conference
6/8/2022
Q32 Bio announced that its Founder and Chief Scientific Officer, Shelia Violette, Ph.D., will present "Targeting Complement in Chronic Inflammatory Disease" at the "Resolution of Inflammation" conference, and is the co-organizer of the "Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies" conference, at the Keystone Symposia on Molecular and Cellular Biology, taking place June 12 through June 16, 2022.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders
5/26/2022
Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that dosing has been initiated in the healthy volunteer portion of its Phase 1, single ascending dose and multiple ascending dose (SAD/MAD) clinical study evaluating ADX-097, a first-in-class fusion protein, for the treatment of complement disorders.
-
Q32 Bio Presents Preclinical Data Highlighting the Design and Characterization of Lead Program for Innate Immunity, ADX-097, at the 28th International Complement Virtual Workshop 2021
12/13/2021
Q32 Bio today announced preclinical data for the Company's lead program for innate immunity, ADX-097.
-
Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021
10/18/2021
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that it will present preclinical data supporting the Company's lead program for innate immunity, ADX-097, during an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2021, taking place virtually from November 4 to 7, 2021.
-
BioSpace Movers & Shakers, Aug. 6
8/6/2021
Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers. -
Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors
8/3/2021
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Kathy LaPorte to its Board of Directors.
-
BioSpace Movers & Shakers, July 9
7/9/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Q32 Bio Appoints Adam Cutler as Chief Financial Officer
7/7/2021
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Adam Cutler as Chief Financial Officer.
-
Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer
3/9/2021
Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna , M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team
-
It didn’t take long for Jason Campagna to find a new role after departing Intercept Pharmaceuticals last month. Campagna will take on the role of chief medical officer for Q32 Bio.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
-
Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors
12/22/2020
Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of industry leader Mark Iwicki as Chairman of its Board of Directors
-
Q32 Bio rakes in $60 million Series B as they dose their first patient in IL-7R antibody trial.
-
Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis
10/29/2020
Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures.
-
Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
5/27/2020
Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020